Related Experiment Video
Updated: Apr 14, 2026
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
Abstract:
Glycosphingolipids (GSLs) are essential constituents of cell membranes and lipid rafts and can modulate signal transduction events. The contribution of GSLs in osteoclast (OC) activation and osteolytic bone diseases in malignancies such as the plasma cell dyscrasia multiple myeloma (MM) is not known. Here, we tested the hypothesis that pathological activation of OCs in MM requires de novo GSL synthesis and is further enhanced by myeloma cell-derived GSLs. Glucosylceramide synthase (GCS) inhibitors, including the clinically approved agent N-butyl-deoxynojirimycin (NB-DNJ), prevented OC development and activation by disrupting RANKL-induced localization of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumulation of transcriptional activator NFATc1. GM3 was the prevailing GSL produced by patient-derived myeloma cells and MM cell lines, and exogenous addition of GM3 synergistically enhanced the ability of the pro-osteoclastogenic factors RANKL and insulin-like growth factor 1 (IGF-1) to induce osteoclastogenesis in precursors. In WT mice, administration of GM3 increased OC numbers and activity, an effect that was reversed by treatment with NB-DNJ. In a murine MM model, treatment with NB-DNJ markedly improved osteolytic bone disease symptoms. Together, these data demonstrate that both tumor-derived and de novo synthesized GSLs influence osteoclastogenesis and suggest that NB-DNJ may reduce pathological OC activation and bone destruction associated with MM.
Insights
Glycosphingolipids (GSLs) drive osteoclast activation in multiple myeloma (MM). Inhibiting GSL synthesis with N-butyl-deoxynojirimycin (NB-DNJ) reduced bone destruction in a mouse model of MM.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Glycosphingolipids (GSLs) are vital cell membrane components influencing signal transduction.
- The role of GSLs in osteoclast (OC) activation and multiple myeloma (MM)-associated bone disease remains unclear.
Purpose of the Study:
- To investigate the role of GSLs in pathological osteoclast activation in MM.
- To determine if de novo GSL synthesis and myeloma cell-derived GSLs enhance OC activation.
- To evaluate the therapeutic potential of GSL synthesis inhibitors in MM bone disease.
Main Methods:
- Utilized glucosylceramide synthase (GCS) inhibitors, including N-butyl-deoxynojirimycin (NB-DNJ).
- Assessed OC development and activation markers, including TRAF6, c-SRC, and NFATc1 localization and nuclear accumulation.
- Analyzed GSL profiles in patient-derived myeloma cells and MM cell lines.
- Administered GM3 and NB-DNJ in wild-type mice and a murine MM model.
Main Results:
- GCS inhibitors prevented OC development and activation by disrupting lipid raft signaling pathways.
- GM3 was the predominant GSL in MM cells and enhanced RANKL/IGF-1-induced osteoclastogenesis.
- NB-DNJ treatment reversed GM3-induced increases in OC numbers and activity in vivo.
- NB-DNJ treatment significantly ameliorated osteolytic bone lesions in a murine MM model.
Conclusions:
- Both tumor-derived and endogenously synthesized GSLs are critical for pathological osteoclastogenesis in MM.
- Inhibiting GSL synthesis with NB-DNJ effectively reduces OC activation and MM-related bone destruction.
- NB-DNJ represents a potential therapeutic strategy for managing osteolytic bone complications in multiple myeloma.
More Related Videos
11:29Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017